Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06078865

FX Shoulder Prospective Clinical Study

Prospective Multi-Center Registry on study subjects with implanted devices marketed and legally commercialized in the USA by FX Shoulder Solutions.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

OrthoArizona, Gilbert, Arizona, United States

Loading trial locations.

About this study

To evaluate patient outcomes following shoulder replacement with FX Shoulder Solutions medical devices and demonstrate effectiveness, safety and survivorship of FX Shoulder Solutions medical devices.

To provide data and analysis to FX Shoulder Solutions to meet regulatory requirements.

To provide data and analysis for presentations, abstracts, publications and other public release of results.

A patient is considered a success at minimum of 2 years post-operative follow-up based upon the following composite clinical success (CCS):

  • Adjusted Constant Score that is ≥ 54 and improvement of ≥ 10 points from baseline
  • No continuous radiolucency or device migration/subsidence
  • No revision surgery
  • No serious device related adverse event

The Registry will continue to follow patients to 10 years post-operative to track survivorship.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Receive an FX shoulder replacement medical device in accordance with the Indications for Use for the selected device system.

Exclusion criteria

Patient who does not meet the inclusion criteria.

Treatment and study plan

FX Artificial Shoulder Prosthesis

Device

Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System, Easytech Anatomical Shoulder System, FXV135 Mini Shoulder System, FXV135 Humelock Shoulder System

Primary outcomes

  1. A patient is considered a success at post-operative follow-up based upon the following composite clinical success (CCS):

    Time frame: 2 years

    Adjusted Constant Score that is ≥ 54 and improvement of ≥ 10 points from baseline.

    No continuous radiolucency or device migration/subsidence No revision surgery No serious device related adverse event.

  2. Survivorship

    Time frame: 10 years

    Follow patient's post-operative to track survivorship.

Secondary outcomes

  1. Adjusted Constant Score

    Time frame: 6 weeks, 3, 6, 12, and 24 months.

    The Constant-Murley score (CMS) is a validated 100-points scale composed of a number of individual parameters. These parameters define the level of pain and the ability to carry out the normal daily activities of the patient. The test is divided into four subscales: pain (15 points), activities of daily living (20 points), strength (25 points) and range of motion (40 points) with the subject completing the assessment prior to the Investigator completing their part of the assessment. The higher the score, the higher the quality of the function.

    An Adjusted Constant score will be calculated using normalized values to account for age and gender, as based upon anatomical gender at birth.

  2. QuickDASH

    Time frame: 6 weeks, 3, 6, 12, and 24 months.

    QuickDASH measures an individual's ability to complete tasks, absorb forces, and severity of symptoms.

    The QuickDASH tool uses a 5-point Likert scale from which the patient can select an appropriate number corresponding to his/her severity level/ function level. The higher the score, the higher the function and lower pain in the patient.

  3. American Shoulder and Elbow Surgeon (ASES)

    Time frame: 6 weeks, 3, 6, 12, and 24 months

    ASES is a validated patient-reported outcome which is composed of 10 functional questions and one pain VAS. The total score is of 100 maximum points and weighted evenly between pain and function

  4. Visual Analog Scale (VAS).

    Time frame: 6 weeks, 3, 6, 12, and 24 months

    A validated measurement of pain in a patient where 0 indicates no pain and 100 indicates severe pain. The VAS is a straight horizontal line of fixed length.

  5. Range of Motion (ROM)

    Time frame: 6 weeks, 3, 6, 12, and 24 months

    The patient performs active movements in all functional planes for the shoulder. Includes flexion, extension, abduction, adduction and internal and external rotation. Investigator estimates the range of movement and compares the affected with the unaffected shoulder and the normal expected range.

  6. Secondary Surgical Interventions (SSI)

    Time frame: 24 months and at 5 years postoperative

    SSI's are re-operations, revisions, and removals.

  7. Serious Adverse Event

    Time frame: 24 months and at 5 years postoperative

    • Led to a death.
    • Resulted in life threatening illness or injury.
    • Resulted in patient hospitalization or prolongation of existing hospitalization.
    • Resulted in patient disability or permanent damage or required intervention to prevent permanent impairment/damage.
    • Led to a congenital abnormality or birth defect.
  8. Serious Adverse Device Effects (SADE)

    Time frame: 24 months and at 5 years postoperative.

    Adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event.

  9. Radiographic Reviews and Assessments.

    Time frame: 24 months and at 5 years postoperative.

    Monitor implant integrity and signs of implant loosening.

  10. Survival

    Time frame: 24 months and at 5 years

    Subject disposition.

Study contacts

Contact information is provided by the study sponsor or research team.

Brian Rogers, BS

CONTACT

[email protected]

800 280-0775

Brian Wasonga, MHA

CONTACT

[email protected]

800-280-0775

Sponsors and collaborators

Lead sponsor

FX Shoulder Solutions

Industry

Registry information

Official study title

FX Shoulder Post-Market Follow-Up Clinical Study

Important dates

Study start
2021
Primary completion
2031
Study completion
2031
First posted
Oct 12, 2023
Registry last updated
Feb 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.